fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Dorzolamide HCL

All products: Limited Use (codes 171, 172, 387)

Trusopt · DIN 02216205 · 2% · Oph Sol

Limited Use, Reason for Use code 171, 172, 387 required; Health Canada lists this DIN as Cancelled post market since 2025-12-08 — choose a marketed DIN from the same-category list.Discontinued December 8, 2025 · checked November 18, 2026
StatusLimited Use, Reason for Use code 171, 172, 387 required; Health Canada lists this DIN as Cancelled post market since 2025-12-08 — choose a marketed DIN from the same-category list.
Write on scriptone applicable Reason for Use code, 171 or 172 or 387 (criteria below); Health Canada lists this DIN as Cancelled post market since 2025-12-08 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 171, 172, 387
Reason for Use code 171 As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 172 As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 387 For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
Savings card: RxHelp ONE lists Trusopt (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Trusopt · DIN 02216205 Manufacturer: Elvium Life Sciences; listing date 1996-12-19 Health Canada: Cancelled post market since 2025-12-08 · brand TRUSOPT · ATC S01EC03 DORZOLAMIDE · form Solution · route Ophthalmic · ingredients DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 2 % · company Elvium life sciences · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ministry pays: $1.4757 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02216205)

Source record
DIN 02216205: Trusopt Raw flags: sec12=Y, sec3=Y Item: 523600083; group id 623; item number 1590; lccId 00086; manufacturer id ELV Source form: Oph Sol; strength: 2% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $6.1267; ministry $1.4757 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02216205 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20083
Interchangeable products
Dorzolamide · DIN 02522373 · $1.4757 Jamp-Dorzolamide · DIN 02453347 · $1.4757 Med-Dorzolamide · DIN 02457210 · $1.4757 Sandoz Dorzolamide · DIN 02316307 · $1.4757
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since December 8, 2025 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (S01E, S01EC): coverage varies; not interchangeable

  • Acetazolamide: general benefit, not a benefit
  • Methazolamide (Neptazane): general benefit, not a benefit
  • Brinzolamide (Azopt): limited Use 171, 172, 387
  • Brimonidine + brinzolamide (Simbrinza): limited Use 466, 393
  • Betaxolol (Betoptic S): general benefit
  • Levobunolol (Betagan): general benefit

11 more in the class list below

Other drugs in the same formulary class (52:36 Other Eye, Ear, Nose and Throat Agents) and how they are covered

Matched class: 52:36 Other Eye, Ear, Nose and Throat Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BETAXOLOL HCL, DICLOFENAC SODIUM, LEVOBUNOLOL HCL Some products covered without a code (check the product listing): ACETAZOLAMIDE, METHAZOLAMIDE, SODIUM CROMOGLYCATE, TIMOLOL MALEATE 52:36 Other Eye, Ear, Nose and Throat Agents

ACETAZOLAMIDE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 250mg · Tab

METHAZOLAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 50mg · Tab

BRINZOLAMIDE

· 1 products · Limited Use, codes 171, 172, 387 · strengths: 1% · Oph Susp

BRINZOLAMIDE & BRIMONIDINE TARTRATE

· 1 products · Limited Use, codes 466, 393 · strengths: 1.0% & 0.2% · Oph Susp-10mL Pk

BETAXOLOL HCL

· 1 products · General benefit · strengths: 0.25% · Oph Susp

LEVOBUNOLOL HCL

· 1 products · General benefit · strengths: 0.5% · Oph Sol

TIMOLOL MALEATE

· 10 products · Listed, not a benefit (2), General benefit (8) · strengths: 0.25%, 0.5% · Oph Gellan Sol, Oph Sol

BIMATOPROST

· 8 products · Listed, not a benefit (1), Limited Use, codes 171, 172, 387 (7) · strengths: 0.03%, 0.01% · Oph Sol, Oph Sol-5mL Pk, Oph Sol-7.5mL Pk

BRIMONIDINE

· 7 products · Limited Use, codes 171, 172, 387 · strengths: 0.15%, 0.2% · Oph Sol

BRIMONIDINE TARTRATE & TIMOLOL MALEATE

· 3 products · Limited Use, codes 310, 393 · strengths: 0.2% & 0.5% · Oph Sol-10mL Pk

BRINZOLAMIDE & TIMOLOL MALEATE

· 1 products · Limited Use, codes 310, 393 · strengths: 1% & 0.5% · Oph Susp-5mL Pk

DORZOLAMIDE HCL & TIMOLOL MALEATE

· 11 products · Limited Use, codes 310, 393 · strengths: 2% & 0.5% · Oph Sol, Oph Sol-0.2mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 52:36 and 20 more
Full class listing Related classes: 52:04 Anti-Infectives, 52:08 Anti-Inflammatory Agents, 52:16 Local Anesthetics, 52:20 Miotics, 52:24 Mydriatics, 52:32 Vasoconstrictors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS Sandoz Dorzolamide (Dorzolamide Hydrochloride Ophthalmic Solution) 2% is indicated in the treatment of elevated intraocular pressure in patients with: • ocular hypertension • open-angle glaucoma 1.1 Pediatrics Pediatrics (<18 years of age): Safety and effectiveness in children have not been established. No data are available to Health Canada; therefore, an indication for pediatric use has not been authorized. 1.2 Geriatrics Geriatrics (>65 years of age): No overall differences in effectiveness or safety were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out (see 7.1.4 Geriatrics). https://pdf.hres.ca/dpd_pm/00075318.PDF PM date: APR 17, 2024 Source product: SANDOZ DORZOLAMIDE; DIN 02316307; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.